-
Je něco špatně v tomto záznamu ?
European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment
GA. Lee, S. Aktaa, E. Baker, CP. Gale, IF. Yaseen, G. Gulati, R. Asteggiano, S. Szmit, A. Cohen-Solal, A. Abdin, W. Jurczak, P. Garrido Lopez, AL. Sverdlov, CG. Tocchetti, A. Barac, I. Parrini, P. Zamorano, Z. Iakobishvili, R. Pudil, L. Badimon,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu přehledy, časopisecké články
NLK
ProQuest Central
od 2016-10-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2016-10-01 do Před 1 rokem
PubMed
36316010
DOI
10.1093/ehjqcco/qcac070
Knihovny.cz E-zdroje
- MeSH
- kardiologie * MeSH
- lékařská onkologie MeSH
- lidé MeSH
- nádory * terapie MeSH
- ukazatele kvality zdravotní péče MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
AIMS: To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity. METHODS AND RESULTS: We followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care: (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy. CONCLUSION: We present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes.
Baghdad Heart Center Baghdad Teaching Hospital Medical City Baghdad Iraq
Cardio oncology Program MedStar Heart and Vascular Institute Washington DC USA
Cardio Oncology Unit Department of Translational Medical Sciences Federico 2 University Naples Italy
Cardiology Department Hôpitaux de Paris Hôpital Lariboisière 2 Rue Ambroise Paré Paris France
Cardiology department La Paz University Hospital IdiPAZ Research Institute Madrid Spain
Department of Cardiology Division of Medicine Oslo University Hospital Ullevål Oslo Norway
Department of Cardiology Leeds Teaching Hospitals NHS Trust Leeds UK
Department of Cardiology Mauriziano Hospital Turin Italy
Department of Community Cardiology Clalit Health Services Tel Aviv Jaffa Israel
Department of Oncology and Hemato Oncology University of Milan Milan Italy
Division of Hematology Oncology Transplantation University of Minnesota Minneapolis MN USA
Faculty of Health Sciences Ben Gurion University of the Negev Beersheba Israel
IIBSant Pau Hospital de la Santa Creu i Sant Pau CiberCV Barcelona Spain
Institute of Hematology and Transfusion Medicine Warsaw Poland
IRCCS European Institute of Oncology Milan Italy
Jefe Servicio Oncología Médica Hospital Universitario Ramón y Cajal Madrid Spain
LARC C so Venezia 10 Turin Italy
Leeds Institute for Data Analytics University of Leeds Leeds UK
Leeds Institute of Cardiovascular and Metabolic Medicine University of Leeds Leeds UK
MSC National Research Institute of Oncology Garnarska 11 31 115 Krakow Poland
Research Medical Unit INSERM U 942 University of Paris Paris France
Royal Marsden NHS Trust and Institute of Cancer Research London UK
School of Medicine Insubria University Varese Italy
Scientific Council of Cardiology Iraqi Board for Medical Specializations Baghdad Iraq
University Hospital Hradec Králové Sokolská 5005 Hradec Králové Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032187
- 003
- CZ-PrNML
- 005
- 20230131151752.0
- 007
- ta
- 008
- 230120s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/ehjqcco/qcac070 $2 doi
- 035 __
- $a (PubMed)36316010
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Lee, G A $u Division of Applied Technology for Clinical Care, Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's College London, James Clerk Maxwell Building, 57 Waterloo Road, London SE1 8WA, UK $1 https://orcid.org/0000000163858600
- 245 10
- $a European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment / $c GA. Lee, S. Aktaa, E. Baker, CP. Gale, IF. Yaseen, G. Gulati, R. Asteggiano, S. Szmit, A. Cohen-Solal, A. Abdin, W. Jurczak, P. Garrido Lopez, AL. Sverdlov, CG. Tocchetti, A. Barac, I. Parrini, P. Zamorano, Z. Iakobishvili, R. Pudil, L. Badimon, AM. Kirby, AH. Blaes, D. Farmakis, G. Curigliano, R. Stephens, AR. Lyon, T. Lopez-Fernandez
- 520 9_
- $a AIMS: To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity. METHODS AND RESULTS: We followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care: (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy. CONCLUSION: We present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ukazatele kvality zdravotní péče $7 D019984
- 650 12
- $a kardiologie $7 D002309
- 650 _2
- $a lékařská onkologie $7 D008495
- 650 12
- $a nádory $x terapie $7 D009369
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Aktaa, S $u Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK $u Leeds Institute for Data Analytics, University of Leeds, Leeds, UK $u Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK $1 https://orcid.org/000000029854481X
- 700 1_
- $a Baker, E $u Division of Applied Technology for Clinical Care, Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's College London, James Clerk Maxwell Building, 57 Waterloo Road, London SE1 8WA, UK
- 700 1_
- $a Gale, C P $u Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK $u Leeds Institute for Data Analytics, University of Leeds, Leeds, UK $u Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
- 700 1_
- $a Yaseen, Israa F $u Baghdad Heart Center, Baghdad Teaching Hospital, Medical City, Baghdad, Iraq $u Scientific Council of Cardiology, Iraqi Board for Medical Specializations, Baghdad, Iraq
- 700 1_
- $a Gulati, G $u Institute of Clinical Medicine, University of Oslo, Oslo, Norway, Division of Research and Innovation, Akershus University Hospital, Lørenskog, Norway $u Department of Cardiology, Division of Medicine, Oslo University Hospital, Ullevål, Oslo, Norway $1 https://orcid.org/0000000213168676
- 700 1_
- $a Asteggiano, R $u School of Medicine, Insubria University, Varese, Italy $u LARC (Laboratorio Analisi e Ricerca Clinica), C.so Venezia 10, Turin, Italy $1 https://orcid.org/0000000222737228
- 700 1_
- $a Szmit, S $u Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, Otwock, Poland $u Institute of Hematology and Transfusion Medicine, Warsaw, Poland $1 https://orcid.org/0000000230751943
- 700 1_
- $a Cohen-Solal, A $u Research Medical Unit INSERM U-942, University of Paris, Paris, France $u Cardiology Department, Hôpitaux de Paris, Hôpital Lariboisière 2 Rue Ambroise Paré, Paris, France $1 https://orcid.org/0000000310552231
- 700 1_
- $a Abdin, A $u Department of Internal Medicine III, Cardiology, Angiology, Intensive Care Medicine, Saarland University Medical Center, Homburg, Germany
- 700 1_
- $a Jurczak, W $u MSC National Research Institute of Oncology, Garnarska 11, 31-115 Krakow, Poland
- 700 1_
- $a Garrido Lopez, P $u Jefe Servicio Oncología Médica, Hospital Universitario Ramón y Cajal, Madrid, Spain $1 https://orcid.org/0000000258996125
- 700 1_
- $a Sverdlov, A L $u Newcastle Centre of Excellence in Cardio-Oncology, Calvary Mater Newcastle, Hunter Medical Research Institute, John Hunter Hospital, University of Newcastle, NSW, Australia
- 700 1_
- $a Tocchetti, C G $u Cardio-Oncology Unit, Department of Translational Medical Sciences (DISMET), Center for Basic and Clinical Immunology Research (CISI), Interdepartmental Center for Clinical and Translational Research (CIRCET), Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University, Naples, Italy
- 700 1_
- $a Barac, A $u Cardio-oncology Program, MedStar Heart and Vascular Institute, Washington DC, USA $1 https://orcid.org/0000000299358904
- 700 1_
- $a Parrini, I $u Department of Cardiology, Mauriziano Hospital, Turin, Italy
- 700 1_
- $a Zamorano, P $u University Hospital Ramon y Cajal, Madrid, Spain
- 700 1_
- $a Iakobishvili, Z $u Department of Community Cardiology, Clalit Health Services, Tel Aviv Jaffa, Israel $u Faculty of Health Sciences, Ben Gurion University of the Negev, Beersheba, Israel
- 700 1_
- $a Pudil, R $u University Hospital Hradec Králové, Sokolská 5005, Hradec Králové, Czech Republic
- 700 1_
- $a Badimon, L $u IIBSant Pau, Hospital de la Santa Creu i Sant Pau, CiberCV, Barcelona, Spain
- 700 1_
- $a Kirby, A M $u Royal Marsden NHS Trust & Institute of Cancer Research, London, UK
- 700 1_
- $a Blaes, A H $u Division of Hematology/Oncology/Transplantation, University of Minnesota, Minneapolis, MN, USA $1 https://orcid.org/0000000254334810
- 700 1_
- $a Farmakis, D $u University of Cyprus Medical School, Nicosia, Cyprus $1 https://orcid.org/0000000183643447
- 700 1_
- $a Curigliano, G $u Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy $u IRCCS, European Institute of Oncology, Milan, Italy
- 700 1_
- $a Stephens, R $u Patient Advocate, London, UK
- 700 1_
- $a Lyon, A R $u National Heart and Lung Institute, Imperial College London, and Cardio-Oncology Service, Royal Brompton Hospital, London, UK
- 700 1_
- $a Lopez-Fernandez, T $u Cardiology department, La Paz University Hospital, IdiPAZ Research Institute, Madrid, Spain
- 773 0_
- $w MED00200141 $t European heart journal. Quality of care & clinical outcomes $x 2058-1742 $g Roč. 9, č. 1 (2022), s. 1-7
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36316010 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131151748 $b ABA008
- 999 __
- $a ok $b bmc $g 1891132 $s 1183522
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 9 $c 1 $d 1-7 $e 2022Dec13 $i 2058-1742 $m European heart journal. Quality of care & clinical outcomes $n Eur Heart J Qual Care Clin Outcomes $x MED00200141
- LZP __
- $a Pubmed-20230120
